IQVIA Holdings (IQV) is in focus after announcing a €950 million senior notes offering due 2033 to refinance existing debt, extend maturities and support an upward revision to its 2026 adjusted earnings per share guidance.

The stock has pulled back this year, with the year to date share price return down 18.6%. However, the 1 year total shareholder return of 20.4% points to longer term momentum building around the story.

If this refinancing and earnings guidance shift has you thinking about where else capital could work hard in healthcare data and software, it is worth scanning 39 healthcare AI stocks

So with IQVIA trading down 18.6% year to date, but sitting against an intrinsic discount of about 41% and a roughly 24% gap to analyst targets, is there still a mispricing here, or is the market already baking in future growth?

Most Popular Narrative: 19.8% Undervalued

With IQVIA last closing at $183.45 against a narrative fair value of $228.60, the current pricing gap hinges on how future earnings play out.

Continued investment in and deployment of proprietary platforms and agentic AI solutions, coupled with strategic collaborations and industry recognitions, increase switching costs and provide competitive barriers, positioning IQVIA to capture greater market share and support long-term revenue growth and margin improvement.

Want to see what is reflected in that valuation gap? Revenue, margins and earnings are all combined into one set of forward-looking assumptions. The surprise is how assertive those earnings and multiples need to be to support the fair value.

Result: Fair Value of $228.60 (UNDERVALUED)

However, analysts also flag that pricing pressure in the CRO market and IQVIA's relatively high leverage could squeeze margins and limit flexibility if conditions become tougher.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With sentiment clearly mixed and the story far from settled, this is the moment to look through the numbers yourself and decide what truly matters for your portfolio, starting with a clear view of the 5 key rewards and 1 important warning sign.

Looking for more investment ideas?

If IQVIA has your attention, do not stop there. Broaden your watchlist now so you do not miss other opportunities shaping the next phase of your portfolio.

• Target reliable cash generators by scanning companies with strong cash flows at reasonable prices using the Simply Wall Street 49 high quality undervalued stocks.
• Strengthen your income stream by reviewing stocks with robust yields and consistent payouts through the focused 9 dividend fortresses.
• Sleep easier at night by checking companies with resilient financial profiles and lower risk scores across the carefully filtered 61 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.